US equities
|
NVDA
$204.64
▼-4.22%
INTC
$65.76
▼-28.58%
MU
$884.74
▼-5.30%
AMZN
$240.35
▼-1.41%
AAPL
$344.63
▼-1.23%
SNDK
$1,150.89
▼-13.47%
AMD
$504.80
▼-10.88%
MSFT
$521.91
▼-1.55%
NVDA
$204.64
▼-4.22%
INTC
$65.76
▼-28.58%
MU
$884.74
▼-5.30%
AMZN
$240.35
▼-1.41%
AAPL
$344.63
▼-1.23%
SNDK
$1,150.89
▼-13.47%
AMD
$504.80
▼-10.88%
MSFT
$521.91
▼-1.55%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Articles published by SetPoint Medical
Rush University Medical Center Performs First SetPoint System Procedures in Chicago for Treatment of Rheumatoid Arthritis
February 03, 2026
From
SetPoint Medical
Via
Business Wire
Landmark RESET-RA Study Published in Nature Medicine Demonstrates Durable Efficacy and Safety of the SetPoint System for Rheumatoid Arthritis
January 05, 2026
From
SetPoint Medical
Via
Business Wire
SetPoint Medical to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 15, 2025
From
SetPoint Medical
Via
Business Wire
SetPoint Medical to Present at Piper Sandler 37th Annual Healthcare Conference
November 25, 2025
From
SetPoint Medical
Via
Business Wire
SetPoint Medical Announces CMS Transitional Pass-Through Payment Approval for the SetPoint System, the Breakthrough Neuroimmune Modulation Platform
November 24, 2025
From
SetPoint Medical
Via
Business Wire
SetPoint Medical to Present Data at ACR Convergence 2025 Demonstrating Sustained Efficacy and Safety for the SetPoint System to Treat Rheumatoid Arthritis
October 25, 2025
From
SetPoint Medical
Via
Business Wire
SetPoint Medical Raises $140 Million in Private Financing and Expands Leadership Team to Support Commercialization of Rheumatoid Arthritis Therapy
August 11, 2025
From
SetPoint Medical
Via
Business Wire
SetPoint Medical Receives FDA Approval for Novel Neuroimmune Modulation Therapy for Rheumatoid Arthritis
July 31, 2025
From
SetPoint Medical
Via
Business Wire
SetPoint Medical Receives Clinical Research Award at EULAR 2025 Congress
June 11, 2025
From
SetPoint Medical
Via
Business Wire
SetPoint Medical Appoints Tyler Binney to Its Board of Directors
June 04, 2025
From
SetPoint Medical
Via
Business Wire
SetPoint Medical Announces Filing of Premarket Approval (PMA) Application to the U.S. Food and Drug Administration (FDA) for Novel Neuroimmune Modulation Device for the Treatment of Rheumatoid Arthritis
December 09, 2024
From
SetPoint Medical
Via
Business Wire
SetPoint Medical Announces Late-Breaking Data from RESET-RA Study at ACR Convergence 2024
November 18, 2024
From
SetPoint Medical
Via
Business Wire
SetPoint Medical Receives FDA’s IDE Approval for U.S. Pilot Study of Neuroimmune Modulation Platform in Adults with Relapsing-Remitting Multiple Sclerosis
October 02, 2024
From
SetPoint Medical
Via
Business Wire
SetPoint Medical Announces Positive Topline Results from Landmark RESET-RA Study Evaluating Neuroimmune Modulation for the Treatment of Rheumatoid Arthritis
July 10, 2024
From
SetPoint Medical
Via
Business Wire
SetPoint Medical Accepted into FDA Total Product Life Cycle Advisory Program for Development of its Neuroimmune Modulation Platform for the Treatment of Multiple Sclerosis
March 21, 2024
From
SetPoint Medical
Via
Business Wire
SetPoint Medical Receives FDA Breakthrough Device Designation for its Neuroimmune Modulation Platform for the Treatment of Multiple Sclerosis
March 13, 2024
From
SetPoint Medical
Via
Business Wire
SetPoint Medical Announces Publication of Data for Neuroimmune Modulation to Treat Crohn's Disease in Journal of Crohn's and Colitis
October 03, 2023
From
SetPoint Medical
Via
Business Wire
SetPoint Medical Appoints Rohan Seth as Chief Financial Officer
June 12, 2023
From
SetPoint Medical
Via
Business Wire
SetPoint Medical Announces Expanded $65M Credit Facility to Support Development of the Company’s Novel Platform for Rheumatoid Arthritis
January 19, 2023
From
SetPoint Medical
Via
Business Wire
Tickers
RWAY
SetPoint Medical Announces $80M Preferred Stock Financing to Advance Company’s Novel Treatment for Autoimmune Diseases
January 19, 2023
From
SetPoint Medical
Via
Business Wire
First Patient Enrolled in Stage 2 of Pivotal Study of SetPoint Medical’s Pioneering Technology for the Treatment of Rheumatoid Arthritis
October 10, 2022
From
SetPoint Medical
Via
Business Wire
SetPoint Medical Announces FDA Approval for Continuation of the RESET-RA Pivotal Study
September 13, 2022
From
SetPoint Medical
Via
Business Wire
